Division of Thermo Fisher Scientific Inc.
Latest From eBioscience Inc.
Medical device companies raised $800 million in the fourth quarter of 2011, and venture capital represented half of that amount. Just over $4 billion was spent to acquire medical device companies, down 50% from Q3’s $8 billion. In vitro diagnostics/research financings were well above the previous quarter, raking in a total of $269 million, with late-stage rounds again bringing in most of the Q4 money. Only five M&A deals were completed, totalling $915 million – way down from Q3’s $2.8 billion for the same number of deals.
Key trends include gene sequencing and approval in tandem of drugs and diagnostics.
Otsuka and Lundbeck signed a long-term CNS collaboration worth $1.4 billion. Gilead spent $10.4 billion on HCV company Pharmasset, the largest amount ever paid for a clinical-stage biotech. Late venture financing and follow-on public offerings represented half of the $945 million that biopharma companies raised. Later-stage rounds were also popular with device companies, which took in $156 million through that financing type, 66% of the $236 million raised.
In Vitro Diagnostics
- Chemistry, Immunoassay
- Molecular Diagnostics & Genetic Testing
- Research, Analytical Equipment & Supplies
- Therapeutic Areas
- Immune Disorders
- North America
- Parent & Subsidiaries
- Thermo Fisher Scientific Inc.
- Senior Management
- Don Tartre, CEO
- Contact Info
Phone: (858) 642-2058
10255 Science Ctr. Dr.
San Diego, CA 92121
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.